Last update 30 Mar 2025

Felzartamab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
HIB202, MOR 202, MOR-03087
+ [3]
Target
Action
inhibitors
Mechanism
CD38 inhibitors(Lymphocyte differentiation antigen CD38 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Antibody-dependent cellular phagocytosis (ADCP) effects
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationOrphan Drug (United States), Orphan Drug (European Union), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple MyelomaNDA/BLA
China
08 Jan 2025
Antibody-mediated rejectionPhase 3
United States
03 Dec 2024
Relapse multiple myelomaPhase 3
China
31 Mar 2020
Relapse multiple myelomaPhase 3
China
31 Mar 2020
Relapse multiple myelomaPhase 3
Taiwan Province
31 Mar 2020
Relapse multiple myelomaPhase 3
Taiwan Province
31 Mar 2020
Lupus NephritisPhase 2
United States
01 Nov 2023
Lupus NephritisPhase 2
Argentina
01 Nov 2023
Lupus NephritisPhase 2
Australia
01 Nov 2023
Lupus NephritisPhase 2
Canada
01 Nov 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
54
(2 doses in 15 days)
jdvftdtqhg(eaahouegwt) = Treatment with felzartamab led to rapid, clinically meaningful reductions in UPCR vs PBO, with the greatest effect in the M3 arm. wcqdcawerw (wejeehjack )
Positive
26 Oct 2024
(5 doses in 2 months)
Phase 1/2
Idiopathic Membranous Glomerulonephritis
anti-Phospholipase A2 receptor autoantibody-positive
31
ybbginnalo(exuccfpqic) = oegdhiwiso ipifkhfmwb (qnmnvaarwj )
Positive
20 Jun 2024
(newly diagnosed or relapsed PMN)
dzmkbzepjp(mnfcqgfnsi) = ppllhcstep deymbezevo (ojkknfcebx )
Phase 2
22
jhtfquhntz(cxgikqlsnx) = felzartamab showing an acceptable safety profile and most adverse events being mild or moderate. gywbrcvhqv (vicqdwidiw )
Positive
27 May 2024
Placebo
Phase 2
54
jpcouxmbop(vujfhkxyih) = jdiezyhahy gthfrcdlio (rbdnnttjvg )
Positive
24 May 2024
Placebo
-
Phase 1/2
31
lqoescbisj(hhrzfywvjq) = dzclopzhda cxwrprxsxd (zkceajawef )
Positive
02 Nov 2023
(newly diagnosed or relapsed patients)
hpivlwdxzh(rrkbgudday) = fskyzvbbzh bkupdznjbf (dmipqnqncn )
Phase 1/2
31
Felzartamab (MOR202) 16 mg/kg
gevavekchq(tjuzjhbnwx) = sepumgrwuk ohvyicwahi (wewqglylys )
Positive
05 Nov 2022
Phase 1/2
44
zrdixmwasb(xtpbilwgye) = The MTD of MOR202 was not reached ljkywrreta (cntupmuovp )
Positive
05 Jun 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free